An exhaust air energy recovery turbine generator is designed to recover part of the energy in the discharged air from an exhaust air system. The design is a combination of H-rotor vertical axis wind turbines (installed in cross-wind position), guide-vanes and a diffuser. Its working principle was tested on a scaled model of cooling tower and simulated in a computational fluid dynamic (CFD) package. From the guide-vanes study, optimum guide-vanes arrangement is 100°, 70° and 90°. The system with optimized guidevanes arrangement produced the highest torque coefficient compared to the other configurations. The average torque coefficient of the system was increased by 24.3% with the introduction of diffuser and guide-vanes at optimized angles, i.e. from 0.029 to 0.036. From the graph of the torque coefficient versus azimuth angle, the overall positive torque zone was increased with the introduction of the guide-vanes with optimum configuration. The exhaust air energy recovery turbine generator can be another green technology that recovers waste energy from the discharged wind of an exhaust air system for urban areas.

-Purpose:To assess the predicted rate and the factors associated with bleeding events among patients with non-valvular atrial fibrillation (NVAF) receiving dabigatran therapy. Methods: This retrospective cohort study includes adult patients of two tertiary hospitals in Malaysia. Potential study subjects were identified using pharmacy supply database or novel oral anticoagulant (NOAC) registry. Demographics, clinical data and laboratory test results were extracted from the medical records of the patients or electronic databases. The main outcome measure is the occurrence of a bleeding event. Bleeding events were classified into major bleeding, clinically relevant non-major bleeding, or minor bleeding, according to the International Society on Thrombosis and Haemostasis criteria. We consider clinically relevant non-major bleeding events or major bleeding events as clinically relevant bleeding events. An occurrence of any bleeding event was recorded from the initiation of NOAC therapy until the death of a patient, or the date of permanent discontinuation of NOAC use, or the last day of data collection. The predicted rate of dabigatran-induced bleeding events per 100 patient-years was estimated. Results: During a median follow-up period of 18 months, 73 patients experienced 90 bleeding events. Among these patients, 25 including 4 fatal cases, experienced major bleeding events. The predicted rate per 100 patientyears of follow-up of any bleeding events was 9.0 [95% CI 6.9 to 11.1]; clinically relevant bleeding events 6.0 [95% CI 4.8 to 8.3], and major bleeding events 3.0 [95% CI 1.9 to 4.2]. The independent risk factor for clinically relevant bleeding events is prior bleeding. While prior bleeding or congestive heart failure is linked with major bleeding events. Conclusions: The predicted rate for dabigatran-induced major bleeding episodes is low but these adverse events carry a high fatality risk. Preventive measures should target older patients who have prior bleeding or congestive heart failure.